PLoS ONE (Jan 2022)

Vasoactive pharmacological management according to SCAI class in patients with acute myocardial infarction and cardiogenic shock

  • Nanna Louise Junker Udesen,
  • Ole Kristian Lerche Helgestad,
  • Jakob Josiassen,
  • Christian Hassager,
  • Henrik Frederiksen Højgaard,
  • Louise Linde,
  • Jesper Kjaergaard,
  • Lene Holmvang,
  • Lisette Okkels Jensen,
  • Henrik Schmidt,
  • Hanne Berg Ravn,
  • Jacob Eifer Møller

Journal volume & issue
Vol. 17, no. 8

Abstract

Read online

Background Vasoactive treatment is a cornerstone in treating hypoperfusion in cardiogenic shock following acute myocardial infarction (AMICS). The purpose was to compare the achievement of treatment targets and outcome in relation to vasoactive strategy in AMICS patients stratified according to the Society of Cardiovascular Angiography and Interventions (SCAI) shock classification. Methods Retrospective analysis of patients with AMICS admitted to cardiac intensive care unit at two tertiary cardiac centers during 2010–2017 with retrieval of real-time hemodynamic data and dosages of vasoactive drugs from intensive care unit databases. Results Out of 1,249 AMICS patients classified into SCAI class C, D, and E, mortality increased for each shock stage from 34% to 60%, and 82% (p 65mmHg and venous oxygen saturation > 55% were reached in the majority of patients; however, more patients in SCAI class D and E had values below treatment targets within 24 hours (pConclusion Hemodynamic treatment targets were achieved in most patients at the expense of increased vasoactive load and more frequent use of epinephrine for each shock severity stage. Mortality was high regardless of vasoactive strategy; only in SCAI class C, epinephrine was associated with a significantly higher mortality, but the signal was not significant in adjusted analysis.